NAVERIS INC.
Company Snapshot
Company Overview
Naveris Inc., a spin-off from the University of North Carolina, is developing and commercializing liquid biopsy assays for early cancer detection.
The company uses proprietary liquid biopsy technology to capture and analyze cancer associated DNA in the blood. This technology enables increased sensitivity compared to existing ctDNA technologies, and it gives Naveris a competitive advantage for early detection of cancers, particularly virus-related cancers.
The company’s lead test, NavDx, detects Human Papilloma Virus (HPV)-associated head and neck cancers in patients by measuring tumor tissue-modified viral HPV particles in plasma cfDNA using digital droplet PCR. Clinical studies have shown that NavDx identifies early recurrence in patients before they would be identified in current clinical practice, for example, by imaging. The goal is to track HPV-associated head and neck cancer patients to verify that they remain cancer-free after treatment.
NavDx is offered by Naveris through its CLIA laboratory to cancer centers in the U.S.
Company's Business Segments
- Liquid Biopsies : Liquid Biopsies are used for Early Detection, Clinical Management of Viral-Associated Cancers.
Applications/End User Industries
- Biotechnology Research
- Cancer Detection
- Liquid Biopsies
- Clinal Management
- Drug Discovery
- Healthcare
- Drug Validation
- Patient and Drug Selection
